Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Droia Ventures is a global venture capital firm founded in 2021, headquartered in Brussels, Belgium. The firm focuses on supporting young drug development companies that leverage innovative science and technology in therapeutics, particularly in oncology and genetic diseases. Droia Ventures manages over $240 million in assets and has made 42 investments to date, reflecting a commitment to addressing critical challenges in healthcare.
The firm operates with a presence in both North America and Europe, allowing it to tap into diverse markets and foster advancements in healthcare. Droia Ventures has evolved from its original focus on oncology, expanding its mandate to include genetic diseases with the launch of Fund III in 2021. This strategic shift aligns with the growing demand for innovative solutions in the biotech sector.
Notable milestones include the successful closing of Fund III, which raised €220 million specifically targeting genetic diseases. The firm emphasizes hands-on support from company creation through clinical proof of concept, ensuring that its portfolio companies are well-positioned for success in a competitive landscape.
Droia Ventures exclusively invests in therapeutics targeting oncology and genetic diseases. The firm seeks to support early-stage drug development companies that utilize novel science and innovative approaches to tackle previously unsolvable clinical problems. Their investment strategy emphasizes significant patient benefits and improvements over existing standard care.
Investment checks typically range from early-stage funding to larger rounds, reflecting the firm's commitment to nurturing its portfolio companies through various stages of development. Droia Ventures actively engages with its companies, providing strategic guidance and leveraging its extensive network of industry contacts to enhance the chances of success.
The firm looks for founders who demonstrate a strong vision and commitment to addressing critical healthcare challenges. Droia Ventures values innovative technology platforms and scientific insights that can lead to breakthroughs in treatment options for patients suffering from cancer and genetic diseases.
Droia Ventures has a diverse portfolio of 42 companies, focusing on innovative therapeutics in oncology and genetic diseases. Notable portfolio companies include:
This portfolio reflects Droia's commitment to advancing healthcare through innovative drug development, particularly in areas with significant unmet medical needs.
Janwillem Naesens: Managing Partner at Droia Ventures, Janwillem has extensive experience in the biotech sector. He has been instrumental in shaping the firm's investment strategy and expanding its focus beyond oncology to include genetic diseases.
Rez Halse: Partner at Droia Ventures, Rez brings a wealth of knowledge in drug development and investment. He emphasizes the importance of hands-on support for portfolio companies and has been a key figure in the firm's growth.
George Golumbeski: Partner at Droia Ventures, George joined the firm in 2020 and has a strong background in biopharma deal-making. He was a major architect of Celgene's biotech collaboration and acquisition strategy and is involved in both genetic disease and oncology investments.
To pitch Droia Ventures, founders should submit their proposals through the firm's website at droiaventures.com. The pitch deck should include a comprehensive overview of the technology, market opportunity, and the team behind the startup. It is advisable to highlight any preliminary data or validation that supports the business case.
Droia Ventures prefers warm introductions but also accepts direct submissions through their website. Founders can expect a response within a few weeks, depending on the volume of inquiries. Clear and concise communication is essential to capture the attention of the investment team.
Droia Ventures has launched the Droia Genetic Disease Fund, which focuses on early-stage biotech companies developing therapeutics for genetic diseases. The fund aims to raise €220 million and supports companies that align with Droia's investment thesis.
This initiative reflects the firm's commitment to advancing healthcare solutions for genetic diseases and provides an additional avenue for investment in innovative therapeutics.
In March 2026, Droia Ventures confirmed an investment in Unnatural Products, further expanding its portfolio in the biotech sector. This follows a recent investment in Alesta Therapeutics, which raised €65 million in Series A funding in January 2025.
In September 2025, Droia Ventures co-led a Series C round for Frontier Medicines, raising $80 million to support the development of therapies targeting 'undruggable' proteins. This investment highlights the firm's commitment to innovative drug development.
Additionally, Droia Ventures has been actively engaged in the biotech sector, as evidenced by a blog post discussing Vico Therapeutics' patient dosing in a Phase 1/2 trial for Huntington’s Disease and Spinocerebellar Ataxia.
What are Droia Ventures' investment criteria?
Droia Ventures invests in early-stage drug development companies focused on therapeutics for oncology and genetic diseases. The firm looks for innovative technology platforms and scientific insights that address previously unsolvable clinical problems.
How can I apply or pitch to Droia Ventures?
Founders can pitch their ideas through the firm's website at droiaventures.com. It is recommended to include a detailed business plan and information on the technology being developed.
What makes Droia Ventures different from other investors?
Droia Ventures emphasizes hands-on support from company creation through clinical proof of concept. The firm leverages its expertise in drug development and access to a network of industry contacts to enhance the success of its portfolio companies.
What is the geographic scope of Droia Ventures?
The firm operates globally, with a strong presence in both North America and Europe, allowing it to tap into diverse markets and foster advancements in healthcare.
What is the typical check size for investments?
Droia Ventures invests in a range of funding rounds, typically starting from early-stage funding to larger rounds, depending on the needs of the portfolio companies.
What is Droia Ventures' post-investment involvement?
The firm provides ongoing support to its portfolio companies, including strategic guidance, operational support, and access to its extensive network, ensuring that companies are well-positioned for success.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.